Solventum (NYSE:SOLV) Given Buy Rating at BTIG Research

Posted by Doug Wharley on Feb 27th, 2026

Solventum (NYSE:SOLV – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at BTIG Research in a research note issued on Friday,Benzinga reports. They presently have a $100.00 price target on the stock. BTIG Research’s price target indicates a potential upside of 29.45% from the company’s current price.

A number of other research analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of Solventum from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Piper Sandler reissued an “overweight” rating on shares of Solventum in a research report on Wednesday, December 17th. UBS Group reaffirmed a “neutral” rating on shares of Solventum in a research report on Friday, November 21st. Mizuho set a $100.00 price objective on Solventum and gave the stock an “outperform” rating in a report on Tuesday, January 20th. Finally, KeyCorp upgraded shares of Solventum from a “sector weight” rating to an “overweight” rating and set a $97.00 target price for the company in a research report on Monday, January 26th. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $91.36.

Check Out Our Latest Stock Report on Solventum

Solventum Price Performance

Shares of NYSE SOLV opened at $77.25 on Friday. Solventum has a fifty-two week low of $60.70 and a fifty-two week high of $88.20. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.14 and a current ratio of 1.50. The firm’s 50-day simple moving average is $78.73 and its 200 day simple moving average is $76.19. The stock has a market cap of $13.40 billion, a price-to-earnings ratio of 8.90, a PEG ratio of 6.90 and a beta of 0.35.

Solventum (NYSE:SOLV – Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.07. The business had revenue of $2 billion during the quarter, compared to the consensus estimate of $1.96 billion. Solventum had a return on equity of 28.01% and a net margin of 18.13%.Solventum’s revenue was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.41 earnings per share. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. As a group, research analysts anticipate that Solventum will post 6.58 earnings per share for the current fiscal year.

Solventum announced that its board has authorized a stock buyback plan on Thursday, November 20th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to repurchase up to 7.5% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board believes its stock is undervalued.

Institutional Investors Weigh In On Solventum

Hedge funds have recently made changes to their positions in the company. Pacer Advisors Inc. grew its stake in Solventum by 28.2% in the fourth quarter. Pacer Advisors Inc. now owns 17,149 shares of the company’s stock worth $1,359,000 after purchasing an additional 3,768 shares during the period. MV Capital Management Inc. bought a new position in shares of Solventum in the 4th quarter worth about $34,000. T. Rowe Price Investment Management Inc. increased its stake in shares of Solventum by 1,482.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 538 shares of the company’s stock worth $43,000 after acquiring an additional 504 shares in the last quarter. Invesco Ltd. boosted its stake in Solventum by 3.4% during the fourth quarter. Invesco Ltd. now owns 2,930,010 shares of the company’s stock worth $232,174,000 after acquiring an additional 96,236 shares in the last quarter. Finally, Birchwood Financial Partners Inc. bought a new stake in Solventum during the fourth quarter worth about $142,000.

More Solventum News

Here are the key news stories impacting Solventum this week:

Positive Sentiment: Q4 results topped estimates: Solventum reported $1.57 EPS vs. consensus $1.50 and $2.0B revenue vs. $1.96B, signaling solid underlying demand. Solventum beats quarterly estimates on strong demand for surgical products
Positive Sentiment: Management raised/guided FY2026: company set EPS guidance of $6.40–$6.60, above consensus, which supports the stock’s re‑rating on earnings visibility. Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance
Positive Sentiment: End‑market strength in wound care and sterilization drove the beat and organic growth, suggesting durable product demand in core categories. Solventum exceeds earnings estimates in first year as solo company
Neutral Sentiment: Organic vs. reported sales split: organic sales rose ~3.5% but reported sales fell ~3.7% (impacted by the 3M spin‑off), so headline revenue comparisons are distorted. Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance
Neutral Sentiment: Conference call/transcript available with management detail — useful for investors to judge sustainability of margin fixes and growth drivers. Solventum Corp (SOLV) Q4 2025 Earnings Call Highlights: Strong Organic Growth Amid Margin Challenges
Negative Sentiment: Margin pressures flagged on the call/notes — management acknowledged cost and mix headwinds that could limit near‑term margin expansion despite the beat. Solventum Corporation (SOLV) Q4 2025 Earnings Call Transcript
Negative Sentiment: Execution and comparability risk after the 3M spin‑off: analysts warn the new standalone setup creates an earnings test for future growth and margins. Solventum faces earnings test on growth targets after 3M spin-off

About Solventum

(Get Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.